Study of Tranexamic Acid During Air Medical Prehospital Transport Trial (STAAMP trial)
Abstract
The enrollment for this study began at the University of Pittsburgh on 11-JUN-2015. External sites are in the process of submitting their initial IRB application and the community consultation plan is either in the development stage or recently initiated. Pittsburgh Coordinating Center is awaiting IRB approval regarding changes to the protocol language. The primary hypothesis is that the prehospital infusion of tranexamic acid in patients at risk for bleeding will reduce the incidence of 30 day mortality. The secondary hypotheses include that prehospital tranexamic acid will reduce the incidence of hyperfibrinolysis, acute lung injury, multiple organ failure, nosocomial infection, mortality, early seizures, pulmonary embolism and early resuscitation needs, reduce or prevent the early coagulopathy as demonstrated by improving presenting INR and rapid thromboelastography parameters, reduce the early inflammatory response, plasmin levels, leukocyte, platelet and complement activation, and determine the optimal dosing of tranexamic acid post-injury.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- ADA626551
Entities
People
- Barbara J. Early
- Jason Lee Sperry
- Meghan Buck
Organizations
- University of Pittsburgh